News and press releases
Gubra and Bayer AG collaborate to develop next generation cardiorenal treatments
20 September 2021 - Gubra announced the signing of a research collaboration and license agreement with Bayer AG for the development of novel peptide therapeutics to treat cardiorenal diseases.
Drug candidate from obesity collaboration between Gubra and Boehringer Ingelheim enters clinical phase 1 trial
11 August 2021 - The advancement of the first of three collaboration projects between Boehringer Ingelheim and Gubra to the clinic marks the achievement of another key milestone.
Annual results 2020: A thriving core business and razor-sharp biotech profile
28 May 2021 - “From a financial perspective 2020 was a year in top 3 for Gubra. Science-wise, we are talking about a record year in terms of discovery, digitalization, robotization and innovation..." says CEO of Gubra Henrik Blou.
Gubra wins sustainability prize 2020
19 March 2021 - Gubra wins the EY Entrepreneur of the Year Sustainability Prize 2020. The jury recognizes Gubra for our clear attitude in CSR and active efforts for a better climate.
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
01 March 2021 - Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity.
Gubra wins EY Entrepreneur of the Year, Region Zealand 2020
07 December 2020 - Gubra wins EY Entrepreneur of the Year 2020, Region Zealand for the 2nd year in a row. Now we are all set for the country finals 21 January.
Gubra chooses sustainable pension scheme
29 June 2020 - At Gubra, we have accomplished a robust investment solution for all our employees by intentionally opting for a sustainable pension scheme (AP Bæredygtig).
A call for simple and comparable CSR reporting
26 May 2020 - In the company’s first CSR Report for 2019, Gubra sets a new standard for simple and comparable CSR reporting.
A year of solid financial growth, scientific breakthroughs, and strong green commitment
14 May 2020 - In 2019 Gubra maintains strong financial growth based on solid results in both the biotech business and the CRO business. New flagship models in kidney and heart diseases bode well for the scientific development.
Gubra is sponsor of BIKE TO WORK
09 March 2020 - It’s official! Gubra is sponsor of this year’s Danish bike campaign BIKE TO WORK (VI CYKLER TIL ARBEJDE).
Co-financed industrial PhD scholarship from DDA
05 March 2020 - Congratulations to Gubra and PhD student Mathias Bonde Møllerhøj (MSc). We just received a co-financed industrial PhD scholarship from the Danish Diabetes Academy.
Gubra wins prestigious award
30 October 2019 - Gubra ApS is the winner of EY Entrepreneur Of The Year in the Zealand region.
Gubra announces the nomination of a co-invented clinical candidate from first obesity collaboration with Boehringer Ingelheim
28 June 2019 - Boehringer Ingelheim and Gubra announce the nomination of a clinical candidate for the development of novel peptide compounds to treat obesity.
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
29 May 2019 - Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity.
JDRF and Gubra join forces to develop a new glucose responsive insulin for diabetes
18 June 2018 - JDRF and Gubra today announced a partnership to develop a glucose-responsive insulin (GRI) as a treatment for people with insulin-requiring diabetes, such as type 1 diabetes (T1D).
Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments
07 September 2017 - Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity.
Gubra reaches third research milestone under a collaboration agreement with Sanofi
30 August 2017 - Today, Gubra announced the successful conclusion of a research collaboration with Sanofi, focusing on the discovery of novel gastrointestinal peptides that could potentially lead to the development of drugs for the treatment of diabetes and obesity
Gubra announces changes to executive management team
01 June 2016 - Today, Gubra announced a change in its executive management team. In order to continue to stay focused on high scientific standards and to accommodate strong growth going forward in both its client base and revenue, Gubra has appointed CBO Henrik Blou as new CEO.
Gubra announces research collaboration agreement with Sanofi to discover and develop peptide-based drugs targeting diabetes and obesity
23 September 2013 - The new research program initiated between Gubra and Sanofi builds upon the established research consortium between Gubra, Gentofte Hospital and the University of Copenhagen partly funded by the Danish National Advanced Technology foundation.